Mobiquity Report Reveals Top Mobile Health App Features that help to increase patient engagement.
March 20, 2023Business Services
Mobiquity, a digital consultancy that designs and delivers innovative digital products and services for the world’s leading brands, released today …
AbbVie shares results from study for new psoriasis therapy
March 20, 2023Research and Development
AbbVie has announced new 52-week data from a study assessing the efficacy of new IL-23 inhibitor, Skyrizi (risankizumab). Patients with …
QurAlis Corporation announces programme which targets UNC13A mis-splicing in neurodegenerative diseases
March 20, 2023Research and Development
US-based clinical-stage biotechnology QurAlis Corporation has announced the launch of its newest programme to treat neurodegenerative diseases like ALS and …
AstraZeneca and MSD announce MHRA marketing authorisation of Lynparza combination therapy
March 20, 2023Medical Communications
AstraZeneca and MSD have announced that the MHRA has granted marketing authorisation for Lynparza (olaparib) in the UK, when used …
Oxford Nanopore and 4bases collaborate on kit for BRCA1 and BRCA2 gene analysis
March 20, 2023Medical Communications
Oxford Nanopore Technologies and Swiss company 4bases have announced a collaboration making 4bases kits with Oxford Nanopore’s sequencing technology. These …
NICE recommends OXLUMO®▼ (lumasiran) in England as first therapy to treat underlying cause of ultra-rare condition primary hyperoxaluria type 1 (PH1)
March 20, 2023Business Services
MAIDENHEAD, UK, Monday 20th March 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a …
New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing
March 20, 2023Business Services
STEVENAGE, UK, March 20, 2023 – New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in …
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
March 20, 2023Business Services
Basel, March 20, 2023 — Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), …
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
March 20, 2023Business Services
Milan, Italy, March 20, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.
Sun Pharma settles at $75m in industry-wide price-fixing case
March 17, 2023Sales and Marketing
Sun Pharma has decided a settlement of $75m as part of a case surrounding various pharma companies fixing their prices. …
Sanofi to cut insulin prices by 78% starting January 2024
March 17, 2023Sales and Marketing
French pharmaceutical company Sanofi has announced that it will cut the list price of its Lantus (insulin glargine injection) 100 …
FDA approves Novartis’ Tafinlar and Mekinist combination
March 17, 2023Medical Communications
The FDA has approved Novartis’ combination therapy, Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of BRAF V600E low-grade glioma …
CANbridge Pharmaceuticals reports positive long-term data for glioblastoma multiforme drug
March 17, 2023Medical Communications
Chinese biopharmaceutical company CANbridge Pharmaceuticals has announced positive long-term follow-up data from its clinical studies into a glioblastoma multiforme (GBM) …
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer
March 17, 2023Business Services
Addlestone UK, 17 March, 2023 –Astellas Pharma Ltd. (“Astellas”) today announced positive topline results from the Phase 3 EMBARK trial …
Newron to present at the 31st European Congress of Psychiatry
March 17, 2023Business Services
Milan, Italy, March 17, 2023, 7am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused …
iOnctura announces publication of pioneering research describing the unique biological features of roginolisib
March 16, 2023Business Services
Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients …
Great Ormand Street Hospital enters commercial agreement with Leucid Bio
March 16, 2023Medical Communications
Leucid Bio and Great Ormand Street Hospital NHS Foundation Trust (GOSH) have entered a commercial agreement to manufacture Leucid’s lead …
The Association of the British Pharmaceutical Industry suspends Novo Nordisk for two years
March 16, 2023Sales and Marketing
The Association of the British Pharmaceutical Industry (ABPI) has suspended Danish pharmaceutical company Novo Nordisk after “serious breaches” of the …
Seamless Therapeutics launches with $12.5m in financing
March 16, 2023Research and Development
Seamless Therapeutics, a biotech focusing on the therapeutic potential of gene therapies, has announced it received $12.5m (€11.8m) in seed …
Bristol Myers Squibb works with SpaceX to study biomanufacturing in space
March 16, 2023Medical Communications
It was announced last week that the SpaceX Dragon spacecraft will make its journey to the International Space Station (ISS) …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
